ICP-192 for FGFR2 fusion bile duct cancer that spread
Part of Cancer clinical trials.
This Phase 2 trial tests a medicine called ICP-192 in people with intrahepatic bile duct cancer that cannot be removed with surgery and has spread. It is for tumors that have an FGFR2 fusion/rearrangement, especially after prior chemotherapy stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and able to sign consent
- Your cancer is intrahepatic bile duct cancer that can’t be removed or has returned or spread, and it grew after at least one chemotherapy treatment
- Your tumor test shows an FGFR2 fusion or rearrangement (checked by a central lab)
- Your overall health is good enough (ECOG score 0 to 1) and you’re expected to live more than 3 months
- You have at least one measurable tumor spot on scans that can be tracked
- Your organs (blood, liver, kidneys) are strong enough, and you can follow the trial’s pregnancy prevention plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication (tinengotinib) against standard chemotherapy for people with advanced bile duct cancer that has a specific gene change (FGFR2). Doctors want to see if this drug can help shrink or slow the cancer better than current treatments.
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.